Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in Taiwan as part of the expansion phase of its THIO-101 Phase 2 trial. The trial is focused on evaluating ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC) in patients who have been heavily pre-treated and have previously failed treatment with checkpoint inhibitors and chemotherapy. This expansion marks a significant milestone, allowing access to a larger patient pool across Europe and Asia. The trial includes two treatment arms: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy, with Regeneron supplying Libtayo for the combination cohort. As of May 15, 2025, the median overall survival for the 22 patients in the third-line treatment was reported as 17.8 months. The treatment has been generally well-tolerated. Further results from the study will be presented as the trial progresses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250709705403) on July 09, 2025, and is solely responsible for the information contained therein.
精彩评论